RT info:eu-repo/semantics/article
T1 Clinical characteristics and incidence of hemorrhagic complications in patients taking factor Xa inhibitors in Spain: a long-term observational study
A1 Escobar, Carlos
A1 Palacios, Beatriz
A1 Villarreal, Miriam
A1 Gutiérrez, Martín
A1 Capel, Margarita
A1 Hernández, Ignacio
A1 García, María
A1 Lledó, Laura
A1 Arenillas Lara, Juan Francisco
K1 Anticoagulants (Medicine)
K1 Anticoagulantes
K1 Hemorrhage - Treatment
K1 Hemorragia - Tratamiento
K1 Brain - Hemorrhage
K1 Cerebro - Hemorragia
K1 Cerebrovascular disease
K1 Cerebro - Vasos sanguineos - Enfermedades
K1 Gastrointestinal hemorrhage
K1 Digestivo, Aparato - Hemorragia
K1 Cardiology
K1 Pharmacology
K1 Hematology
K1 Neurology
K1 Clinical Medicine
K1 Public health - Spain
K1 Salud pública - España
K1 3205.01 Cardiología
K1 3209 Farmacología
K1 3205.04 Hematología
K1 3205.07 Neurología
K1 3201 Ciencias Clínicas
AB Objective. To analyze the clinical characteristics of patients taking Factor Xa inhibitors (FXai), either direct FXai or enoxaparin (only in active cancer patients), and to estimate the incidence of and risk factors for major bleeding during FXai use. Methods. A retrospective cohort study, which included secondary data from computerized health records of primary care centers and hospitals in seven Spanish Autonomous Communities. Results. 9374 patients were analyzed, with 8972 taking direct FXai and 402 enoxaparin. At baseline, the mean age (SD) was 71.8 (9.4) years, 56.0% were women, 76.3% had hypertension, 33.6% had type 2 diabetes, and 25.5% had heart failure. The most common indication for FXai use was atrial fibrillation (72.3%), followed by venous thromboembolism (22.2%) and non-mechanical cardiac–valve replacement (5.6%). At the end of the follow-up period, the incidence rates of major bleeding overall, gastrointestinal, and intracranial were 10.2, 9.0, and 0.8 per 100 person-years, respectively. The total incidence of fatal major bleeding was 0.5 per 100 person-years. Incidence rates of all bleedings progressively decreased over time, with 62.5% of the first events occurring in the initial three months and reaching 76.8% within six months following initiation of treatment. Only 4.8% of the 1st major bleedings led to death, 2.3% in the case of major gastrointestinal bleeding, and 30.8% after an intracranial bleeding. 65.9% of patients discontinued anticoagulation after experiencing major bleeding. Conclusions. In Spain, patients taking FXai were old and had many comorbidities. Despite incidence rates of major bleeding were high, incidence rates of intracranial and fatal bleedings were low, but more efforts are required due to their relevant clinical impact.
PB MDPI
YR 2024
FD 2024
LK https://uvadoc.uva.es/handle/10324/70208
UL https://uvadoc.uva.es/handle/10324/70208
LA eng
NO Journal of Clinical Medicine, 2024, Vol. 13, Nº. 6, 1677
NO Producción Científica
DS UVaDOC
RD 22-nov-2024